# Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma

> **NCT00003895** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Recurrent Melanoma
- Stage IA Melanoma
- Stage IB Melanoma
- Stage IIA Melanoma
- Stage IIB Melanoma
- Stage IIC Melanoma
- Stage IIIA Melanoma
- Stage IIIB Melanoma
- Stage IIIC Melanoma

## Interventions

- **BIOLOGICAL:** HPV 16 E7:12-20
- **BIOLOGICAL:** gp100:209-217(210M)
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00003895
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-04
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003895, "Vaccine Therapy in Treating HLA-A2 Positive Patients With Melanoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00003895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*